Mechanisms of Accelerated Biological Aging and Premature Cardiovascular Events in Young and Middle-Aged Post-COVID-19 Survivors.

This review evaluates the impact of Post-Acute Sequelae of SARS-CoV-2 on adults aged 25 to 55, focusing on the potential for accelerated biological aging and an increased incidence of acute cardiovascular events. By synthesizing evidence from 110 epidemiological and mechanistic studies, we examine the interplay between viral-induced immune dysregulation, endothelial injury, and systemic physiological decline in a demographic previously considered low-risk for severe outcomes. Our analysis indicates that chronic systemic inflammation, potentially maintained by persistent viral reservoirs in immune-privileged sites, may drive aging-associated molecular changes. While accelerated telomere attrition and altered DNA methylation patterns are reported, applying validated epigenetic clocks (e.g., Horvath's, PhenoAge) yields divergent results, ranging from no disparity to slight but significant epigenetic age acceleration. Alongside these evolving metrics, elevated neurofilament light chain and GDF-15 may indicate ongoing neuronal injury and cellular stress. Concurrently, the findings highlight an elevation in cardiovascular relative risks, where sustained endothelial dysfunction and microthrombi formation appear to contribute to a higher frequency of acute events, including myocardial infarction and ischemic stroke, within these younger cohorts. The review concludes that Post-Acute Sequelae of SARS-CoV-2 may represent an emerging driver of premature biological aging and heightened vascular vulnerability. We propose an exploratory clinical framework that prioritizes targeted, symptom-driven care pathways. While early pharmacological interventions remain strictly hypothesis-generating and confined to clinical trials to prevent iatrogenic harm, utilizing advanced biomarkers to evaluate high-risk phenotypes in symptomatic patients may guide future multidisciplinary research to mitigate the long-term societal burden of post-viral decline.